Kiniksa Pharmaceuticals Ltd.'s (KNSA) flagship product Arcalyst has garnered widespread acclaim and acceptance since its launch in April 2021. With a growing adoption rate, the company has revised upward its revenue forecast for 2024.
Arcalyst is the first and only FDA-approved therapy for recurrent pericarditis, a painful and debilitating auto-inflammatory cardiovascular disease. The drug was licensed from Regeneron in 2017.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com